101 related articles for article (PubMed ID: 10938510)
21. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C.
Guilera M; Forns X; Torras X; Enríquez J; Coll S; Solà R; Morillas R; Planas R; Ampurdanès S; Soler M; Costa J; Sáiz JC; Sánchez-Tapias JM; Rodés J
J Hepatol; 2000 Jul; 33(1):135-41. PubMed ID: 10905597
[TBL] [Abstract][Full Text] [Related]
22. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
Tong MJ; Blatt LM; McHutchison JG; Co RL; Conrad A
Hepatology; 1997 Dec; 26(6):1640-5. PubMed ID: 9398010
[TBL] [Abstract][Full Text] [Related]
23. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.
Izopet J; Payen JL; Alric L; Sandres K; Charlet JP; Vinel JP; Duffaut M; Pascal JP; Puel J
J Med Virol; 1998 Feb; 54(2):86-91. PubMed ID: 9496364
[TBL] [Abstract][Full Text] [Related]
24. Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
Flichman D; Colombatto P; Randone A; Baldi M; Bellati G; Negro F; Oliveri F; Colucci G; Verme G; Bonino F; Brunetto MR
Clin Diagn Virol; 1997 May; 8(1):63-70. PubMed ID: 9248659
[TBL] [Abstract][Full Text] [Related]
25. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
27. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
28. Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use.
Picciotto A; Campo N; Brizzolara R; Sinelli N; Torre F; Cipriani AG; Ponassi I; Varagona G; Grasso A; De Leo P; De Conca V; Mesiti S; Marenco G; Menardo G; Dodero M; Celle G
Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):649-53. PubMed ID: 10418937
[TBL] [Abstract][Full Text] [Related]
29. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
Fong TL; Han SH; Tsai NC; Morgan TR; Mizokami M; Qian D; Phan C; Goad K; Redeker AG
J Hepatol; 1998 Mar; 28(3):369-74. PubMed ID: 9551672
[TBL] [Abstract][Full Text] [Related]
30. Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. The Donor Surveillance Study Group.
Prati D; Zanella A; Zanuso F; Vianello L; Della Torre E; Mozzi F; Carriero PL; Zahm F; Donato MF; Colombo M; Sirchia G
J Viral Hepat; 2000 Sep; 7(5):352-60. PubMed ID: 10971823
[TBL] [Abstract][Full Text] [Related]
31. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Giannini EG; Basso M; Savarino V; Picciotto A
Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
[TBL] [Abstract][Full Text] [Related]
32. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study.
Tassopoulos NC; Vafiadis I; Tsantoulas D; Syrokosta J; Hatzis G; Delladetsima JK; Demonakou M; Sypsa V; Hatzakis AE
J Interferon Cytokine Res; 2002 Mar; 22(3):365-9. PubMed ID: 12034044
[TBL] [Abstract][Full Text] [Related]
33. Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C.
Hagiwara H; Hayashi N; Kasahara A; Oshita M; Katayama K; Naito M; Masuzawa M; Yoshihara H; Shimizu Y; Fusamoto H; Kamada T
Dig Dis Sci; 1996 May; 41(5):1001-7. PubMed ID: 8625742
[TBL] [Abstract][Full Text] [Related]
34. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
35. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
36. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
[TBL] [Abstract][Full Text] [Related]
37. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
38. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
39. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
